Benfotiamine improves dystrophic pathology and exercise capacity in mdx mice by reducing inflammation and fibrosis

Chantal A Coles,Keryn G Woodman,Elizabeth M Gibbs,Rachelle H Crosbie,Jason D White,Shireen R Lamandé

DOI: https://doi.org/10.1093/hmg/ddae066

IF: 5.1214

2024-05-07

Human Molecular Genetics

Abstract:Duchenne Muscular Dystrophy (DMD) is a progressive and fatal neuromuscular disease. Cycles of myofibre degeneration and regeneration are hallmarks of the disease where immune cells infiltrate to repair damaged skeletal muscle. Benfotiamine is a lipid soluble precursor to thiamine, shown clinically to reduce inflammation in diabetic related complications. We assessed whether benfotiamine administration could reduce inflammation related dystrophic pathology. Benfotiamine (10 mg/kg/day) was fed to male mdx mice (n = 7) for 15 weeks from 4 weeks of age. Treated mice had an increased growth weight (5–7 weeks) and myofibre size at treatment completion. Markers of dystrophic pathology (area of damaged necrotic tissue, central nuclei) were reduced in benfotiamine mdx quadriceps. Grip strength was increased and improved exercise capacity was found in mdx treated with benfotiamine for 12 weeks, before being placed into individual cages and allowed access to an exercise wheel for 3 weeks Global gene expression profiling (RNAseq) in the gastrocnemius revealed benfotiamine regulated signalling pathways relevant to dystrophic pathology ( Inflammatory Response, Myogenesis) and fibrotic gene markers ( Col1a1, Col1a2, Col4a5, Col5a2, Col6a2, Col6a2, Col6a3, Lum ) towards wildtype levels. In addition, we observed a reduction in gene expression of inflammatory gene markers in the quadriceps ( Emr1, Cd163, Cd4, Cd8, Ifng ). Overall, these data suggest that benfotiamine reduces dystrophic pathology by acting on inflammatory and fibrotic gene markers and signalling pathways. Given benfotiamine's excellent safety profile and current clinical use, it could be used in combination with glucocorticoids to treat DMD patients.

genetics & heredity,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the inflammatory and fibrotic pathological processes in Duchenne Muscular Dystrophy (DMD). DMD is a progressive and fatal neuromuscular disease, characterized by periodic degeneration and regeneration of muscle fibers, accompanied by infiltration of immune cells to repair damaged skeletal muscles. The paper explores whether Benfotiamine can improve the pathological manifestations of DMD by reducing inflammation and fibrosis. Specifically, the researchers evaluated the effects of Benfotiamine on the DMD mouse model (mdx mice), especially whether it can reduce inflammation - related pathological changes, improve motor ability and grip strength, and regulate gene expression related to inflammation and fibrosis. The research results show that Benfotiamine can indeed reduce the expression of inflammatory markers and fibrotic genes, improve muscle pathology, and enhance muscle function. These findings suggest that Benfotiamine may be used as an adjuvant treatment, in combination with the current standard treatment drug, glucocorticoids, to better treat DMD patients.

Benfotiamine improves dystrophic pathology and exercise capacity in mdx mice by reducing inflammation and fibrosis

A Novel MAO-B/SSAO Inhibitor Improves Multiple Aspects of Dystrophic Phenotype in mdx Mice

Benfotiamine Supplementation Increases Thiamine in Muscle of Endurance-Trained Mice and Affects the Energy Metabolism

Trilobatin contributes to the improvement of myopathy in a mouse model of Duchenne muscular dystrophy

Mitochondrial Transplantation Therapy Ameliorates Muscular Dystrophy in mdx Mouse Model

Moderate-term dimethyl fumarate treatment reduces pathology of dystrophic skeletal and cardiac muscle in a mouse model

Astaxanthin Ameliorates Worsened Muscle Dysfunction of MDX Mice Fed with a High-Fat Diet through Reducing Lipotoxicity and Regulating Gut Microbiota

Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient Mdx Mice Via NF-E2-related Factor 2 (Nrf2)-Mediated Inhibition of NF-κB Signaling Pathway.

Reduction of Mitochondrial Calcium Overload via MKT077-Induced Inhibition of Glucose-Regulated Protein 75 Alleviates Skeletal Muscle Pathology in Dystrophin-Deficient mdx Mice

Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin-Deficient D2.B10-Dmd mdx /J Mouse

Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise

Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy

Chloroquine decreases cardiac fibrosis and improves cardiac function in a mouse model of Duchenne muscular dystrophy

Nifedipine Treatment Reduces Resting Calcium Concentration, Oxidative and Apoptotic Gene Expression, and Improves Muscle Function in Dystrophic mdx Mice

In vivo neutralization of IL-6 receptors ameliorates gastrointestinal dysfunction in dystrophin-deficient mdx mice

Oral administration of plumbagin is beneficial in in vivo models of Duchenne muscular dystrophy through control of redox signaling

LED therapy modulates M1/M2 macrophage phenotypes and mitigates dystrophic features in treadmill-trained mdx mice

An anti-ADAMTS1 treatment relieved muscle dysfunction and fibrosis in dystrophic mice

Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations

Effects of omega-3 on matrix metalloproteinase-9, myoblast transplantation and satellite cell activation in dystrophin-deficient muscle fibers

Beneficial effects of resistance training on both mild and severe mouse dystrophic muscle function as a preclinical option for Duchenne muscular dystrophy